RxDoctor Payments Data

Abigail Leonoras, APRN

Nurse Practitioner · Las Vegas, NVNPI 1326562166

Payments from drug & device makers

$1,210in general payments, 2019–2025

Across 41 payments — averaging $29.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$208
  • GSK$174
  • Vifor Pharma, Inc.$171
  • Sanofi$159
  • Ardelyx, Inc.$124
  • OPKO Pharmaceuticals, LLC$122
  • plus $253 from 7 others

What the payments were for

  • Food & beverage$1,08790%
  • Education$12410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,210 in reported general payments places this provider in the 75th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$41,563
Medicare patients
92
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide121$359,094
AuryxiaFerric Citrate66$108,991
XphozahTenapanor Hcl32$99,746
Sevelamer Carbonate373$53,293
VeltassaPatiromer Calcium Sorbitex57$44,913
FosrenolLanthanum Carbonate18$38,913
Lanthanum Carbonate61$33,547
EliquisApixaban30$27,648
LokelmaSodium Zirconium Cyclosilicate21$9,624
Midodrine Hcl78$3,546
Calcium Acetate54$2,545
Hydralazine Hcl77$1,907
Nifedipine ErNifedipine45$1,312
Labetalol Hcl17$1,246
Lidocaine-PrilocaineLidocaine/Prilocaine49$1,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$20$359,094121 claims
Akebia Therapeutics IncAuryxia$66$108,99166 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →